Core Insights - Junsheng Tai Pharmaceutical-B (02511) announced a collaboration with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences to evaluate the treatment potential of its core product HTD1801 for chronic kidney disease associated with type 2 diabetes (CKD with T2DM) [1] - The project has received approval from the Chinese Academy of Medical Sciences, focusing on innovative drug mechanisms and clinical research for diabetes and chronic kidney disease [1] - This collaboration aims to leverage the resources of the Institute and the company's expertise in metabolic diseases to accelerate clinical development and enhance product application value [1] Product Development - HTD1801 is the core product of Junsheng Tai Pharmaceutical and the main focus of this collaboration, acting as an oral anti-inflammatory and metabolic regulator targeting the gut-liver system [2] - It features a unique dual mechanism that activates AMPK and inhibits the NLRP3 inflammasome, demonstrating potential in improving multiple health indicators such as blood sugar, blood lipids, kidney function, weight, liver function, and cardiovascular health [2] - Over ten global clinical trials have shown HTD1801's potential for treating comorbidities associated with type 2 diabetes, chronic kidney disease, obesity, dyslipidemia, and fatty liver [2]
君圣泰医药-B与中国医学科学院医药生物技术研究所共同开展课题合作 探索创新药代谢与肾脏获益潜力